VEGFR-3在喉癌组织中的表达及临床意义

摘要

Objective To investigate the role of vascular endothelial growth factor receptor-3(VEGFR-3) in the occurrence and development of laryngeal carcinoma and its effect on the prognosis. Methods Forty five specimens of the laryngeal cancer( laryngeal carcinoma group) and twenty specimens of benign laryngeal diseases( benign group) were studied. The protein and mRNA expression of VEGFR-3 were observed by immunohistochemistry and real-time fluorescent quantitative PCR. The correlation analysis was made between VEGFR-3 and clinical parameters, and the role of VEGFR-3 in laryngeal cancer prognosis was judged by using Log-rank method. Results The positive expression rate of VEGFR-3 protein in benign group benign group were 44.4％, 15.0％, and the expression of VEGFR-3 mRNA were 10.4 ± 2.7,2.3 ± 0.6,comparison between the two groups showed that P ＜ 0.01. The expression of VEGFR-3 was significantly correlated with lymphatic metastasis and lymphovascular invasion, no significant correlation was found with the age, gender, histological stage, TNM stage and location. The mean survival time for cases with VEGFR-3 positive expression was 50 months, while the cases with VEGFR-3 negative expression was 60 months ( P ＞ 0.05). Conclusion The expression of VEGFR-3 is cotrelated with lymphatic metastasis of laryngeal carcinoma, but not with the prognosis.%目的 探讨血管内皮生长因子受体-3(VEGFR-3)在喉癌发生、发展中的作用及对预后的影响.方法 选择手术切除的喉癌组织标本45份(喉癌组),喉良性病变组织标本20份(良性组),采用免疫组化法检测两组VEGFR-3蛋白的表达,实时荧光定量PCR法检测VEGFR-3 mRNA表达;分析VEGFR-3与喉癌临床病理特征的关系,应用Log-rank检验分析VEGFR-3表达与喉癌预后的关系.结果 喉癌组及良性组VEGFR-3的阳性率分别为44.4%、15.0%、VEGFR-3 mRNA的相对表达量分别为10.4±2.7、2.3±0.6,两组比较P均＜0.01; VEGFR-3表达与喉癌淋巴结转移、淋巴管浸润密切相关,而与年龄、性别、肿瘤部位、组织学分级、TN M分期无关;喉癌组VEGFR-3阳性及阴性表达者平均生存时间分别为50、60个月,P>0.05.结论 VEGFR-3与喉癌淋巴结转移相关,但与预后无明显相关性.